Ken Cacciatore
Stock Analyst at TD Cowen
(0.34)
# 4,328
Out of 5,150 analysts
12
Total ratings
30%
Success rate
-28.61%
Average return
Main Sectors:
Stocks Rated by Ken Cacciatore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $65 → $50 | $24.12 | +107.30% | 2 | Aug 9, 2023 | |
| BHC Bausch Health Companies | Downgrades: Market Perform | n/a | $5.63 | - | 1 | Jun 16, 2023 | |
| TAK Takeda Pharmaceutical Company | Maintains: Outperform | $30 → $20 | $18.22 | +9.77% | 4 | May 16, 2023 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $35 | $18.05 | +93.91% | 1 | May 11, 2022 | |
| MOLN Molecular Partners AG | Initiates: Outperform | $50 | $5.11 | +878.47% | 1 | Jul 13, 2021 | |
| TARA Protara Therapeutics | Initiates: Outperform | $50 | $6.20 | +706.45% | 1 | Oct 19, 2020 | |
| BHVN Biohaven | Initiates: Outperform | $45 | $10.61 | +324.13% | 1 | Apr 17, 2020 | |
| AMRN Amarin Corporation | Initiates: Outperform | $460 | $14.54 | +3,063.69% | 1 | Mar 2, 2020 |
Arcutis Biotherapeutics
Aug 9, 2023
Maintains: Outperform
Price Target: $65 → $50
Current: $24.12
Upside: +107.30%
Bausch Health Companies
Jun 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $5.63
Upside: -
Takeda Pharmaceutical Company
May 16, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $18.22
Upside: +9.77%
Bausch + Lomb
May 11, 2022
Initiates: Outperform
Price Target: $35
Current: $18.05
Upside: +93.91%
Molecular Partners AG
Jul 13, 2021
Initiates: Outperform
Price Target: $50
Current: $5.11
Upside: +878.47%
Protara Therapeutics
Oct 19, 2020
Initiates: Outperform
Price Target: $50
Current: $6.20
Upside: +706.45%
Biohaven
Apr 17, 2020
Initiates: Outperform
Price Target: $45
Current: $10.61
Upside: +324.13%
Amarin Corporation
Mar 2, 2020
Initiates: Outperform
Price Target: $460
Current: $14.54
Upside: +3,063.69%